Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Defense Minister Katz moves to extend IDF service to 36 months - 2A Couple of Reasonable Guitars for 2024
- 3In Antarctica, photos show a remote area teeming with life amid growing risks from climate change
- 4Tracking down the Right Equilibrium: Charges versus Personal Costs in Senior Protection.
- 510 Famous Frozen yogurt Flavors All over The Planet
- Figure out How to Adjust Work, Life, and an Internet based Degree
- 6 Useful Home Espresso Machines
- Blue Origin launches huge rocket carrying twin NASA spacecraft to Mars
- A Pompeii site reveals the recipe for Roman concrete. It contradicts a famous architect’s writings
- Polar bears are rewiring their own genetics to survive a warming climate
- FDA official discusses potential link between COVID-19 vaccines and pediatric deaths
- Ocean side Locations for a Family Excursion
- The most effective method to Pick the Right Material Organization: Your Definitive Aide
- When darkness shines: How dark stars could illuminate the early universe
